Switch theme
Sign up to access all valuation multiples
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2025, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 38% of Terumo’s revenue.
1921
26.5K+
LTM Revenue $7.2B
LTM EBITDA $1.7B
$26.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Terumo has a last 12-month revenue (LTM) of $7.2B and a last 12-month EBITDA of $1.7B.
In the most recent fiscal year, Terumo achieved revenue of $6.3B and an EBITDA of $1.5B.
Terumo expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Terumo valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.2B | XXX | $6.3B | XXX | XXX | XXX |
| Gross Profit | $3.9B | XXX | $3.3B | XXX | XXX | XXX |
| Gross Margin | 54% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $1.7B | XXX | $1.5B | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBIT | $1.1B | XXX | $961M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $836M | XXX | $730M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $185M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Terumo's stock price is JPY 2661 (or $18).
Terumo has current market cap of JPY 3.92T (or $26.9B), and EV of JPY 3.88T (or $26.6B).
See Terumo trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.6B | $26.9B | XXX | XXX | XXX | XXX | $0.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Terumo has market cap of $26.9B and EV of $26.6B.
Terumo's trades at 4.3x EV/Revenue multiple, and 18.2x EV/EBITDA.
Equity research analysts estimate Terumo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Terumo has a P/E ratio of 32.2x.
See valuation multiples for Terumo and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $26.9B | XXX | $26.9B | XXX | XXX | XXX |
| EV (current) | $26.6B | XXX | $26.6B | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 15.7x | XXX | 18.2x | XXX | XXX | XXX |
| EV/EBIT | 23.6x | XXX | 28.8x | XXX | XXX | XXX |
| EV/Gross Profit | 6.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 32.2x | XXX | 38.4x | XXX | XXX | XXX |
| EV/FCF | 28.3x | XXX | 62.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTerumo's last 12 month revenue growth is 4%
Terumo's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Terumo's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Terumo's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Terumo and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 28% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Terumo acquired XXX companies to date.
Last acquisition by Terumo was XXXXXXXX, XXXXX XXXXX XXXXXX . Terumo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Terumo founded? | Terumo was founded in 1921. |
| Where is Terumo headquartered? | Terumo is headquartered in Japan. |
| How many employees does Terumo have? | As of today, Terumo has 26.5K+ employees. |
| Who is the CEO of Terumo? | Terumo's CEO is Mr. Hikaru Samejima. |
| Is Terumo publicy listed? | Yes, Terumo is a public company listed on TKS. |
| What is the stock symbol of Terumo? | Terumo trades under 4543 ticker. |
| When did Terumo go public? | Terumo went public in 1982. |
| Who are competitors of Terumo? | Similar companies to Terumo include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Terumo? | Terumo's current market cap is $26.9B |
| What is the current revenue of Terumo? | Terumo's last 12 months revenue is $7.2B. |
| What is the current revenue growth of Terumo? | Terumo revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Terumo? | Current revenue multiple of Terumo is 3.7x. |
| Is Terumo profitable? | Yes, Terumo is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Terumo? | Terumo's last 12 months EBITDA is $1.7B. |
| What is Terumo's EBITDA margin? | Terumo's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Terumo? | Current EBITDA multiple of Terumo is 15.7x. |
| What is the current FCF of Terumo? | Terumo's last 12 months FCF is $940M. |
| What is Terumo's FCF margin? | Terumo's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Terumo? | Current FCF multiple of Terumo is 28.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
